Equities

BioRestorative Therapies Inc

BioRestorative Therapies Inc

Actions
FinancialsInvestment Banking and Brokerage Services
  • Price (USD)1.45
  • Today's Change0.005 / 0.35%
  • Shares traded32.49k
  • 1 Year change-22.04%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.

  • Revenue in USD (TTM)377.00k
  • Net income in USD-6.17m
  • Incorporated2022
  • Employees11.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Yubo International Biotech Ltd25.78k-2.00m9.71m18.00------376.47-0.0167-0.01670.0002-0.02610.01450.04670.19351,432.22-120.65------80.41---8,325.41--0.1598-17,544.82----479.86--0.8224------
Senti Biosciences Inc0.00-70.87m9.71m48.00--0.608-----15.59-15.600.003.490.00----0.00-74.80---83.22--------------0.0064---40.25---67.94------
BioCardia Inc71.00k-7.72m9.79m16.00--3.51--137.85-4.22-4.220.0360.60860.0142--1.254,437.50-154.22-107.34-401.77-154.17-----10,876.06-1,779.24----0.00---64.72-5.262.82---28.89--
Kiora Pharmaceuticals Inc16.02m5.55m9.93m12.005.410.33081.780.62-0.5993-0.59934.8910.010.5889--9.181,335,000.0020.40-70.5222.75-81.86----34.64-2,040.61----0.00------3.97------
BioRestorative Therapies Inc377.00k-6.17m10.00m11.00--1.00--26.52-0.7135-0.71350.05461.440.0266--3.6934,272.73-43.49-192.11-53.99-329.3279.04---1,636.79-19,116.15----0.00--21.705.6143.67--67.77--
Imunon Inc0.00-19.45m10.05m33.00--1.23-----1.89-1.890.000.56490.00----0.00-99.63-50.18-137.53-60.27-------5,725.88----0.00---100.00--45.64--26.69--
Vaccinex Inc388.00k-18.58m10.06m37.00------25.93-12.15-12.150.2512-0.50810.1047--0.404610,486.49-501.27-262.29---------4,787.89-4,257.17---49.48----107.27-4.67-2.20---22.20--
Dominari Holdings Inc12.59m-22.69m10.23m26.00--0.2673--0.8126-3.85-3.852.116.100.2361--3.80484,192.30-42.55-26.82-44.27-27.45-----180.22-3,353.52---4.830.00----135.7512.72--63.99--
Oncotelic Therapeutics Inc0.00-4.66m10.31m22.00--1.17-----0.0115-0.01150.000.02170.00----0.00-17.29-25.03-39.98-48.76-------1,692.93---0.50090.614-------255.12------
ELEVAI Labs Inc2.45m-5.47m10.46m18.00--0.1166--4.27-0.2924-0.29240.13030.17330.38260.9499216.67135,897.80-85.53---121.34--71.15---223.57--3.40--0.00--123.50---138.94------
CeCors Inc-100.00bn-100.00bn10.46m6.00---------------0.0163------------------------------------22.70------
Indaptus Therapeutics Inc0.00-14.89m10.66m7.00--1.77-----1.72-1.720.000.58870.00----0.00-114.42-66.55-138.96-81.23------------0.00-------7.68------
Viaderma Inc17.80m2.31m10.73m75.000.00050.000031.980.60316.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Turnstone Biologics Corp0.00-74.42m10.86m81.00--0.2488-----3.23-3.230.001.890.00----0.00-78.42---91.27--------------0.00---73.66---78.05------
Data as of Nov 22 2024. Currency figures normalised to BioRestorative Therapies Inc's reporting currency: US Dollar USD

Institutional shareholders

13.52%Per cent of shares held by top holders
HolderShares% Held
Auctus Fund Management LLCas of 30 Sep 2024681.23k9.84%
Geode Capital Management LLCas of 30 Sep 202455.71k0.81%
StoneX Group, Inc. (Investment Management)as of 30 Sep 202450.10k0.72%
The Wealth Alliance LLC (New York)as of 30 Sep 202440.00k0.58%
The Vanguard Group, Inc.as of 30 Sep 202420.47k0.30%
SSgA Funds Management, Inc.as of 30 Sep 202420.46k0.30%
Renaissance Technologies LLCas of 30 Sep 202420.00k0.29%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 202417.50k0.25%
US Financial Advisors LLCas of 30 Sep 202417.14k0.25%
G1 Execution Services LLCas of 30 Sep 202412.77k0.19%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.